CO2022004743A2 - Anticuerpos dirigidos a flt3 y uso de los mismos - Google Patents
Anticuerpos dirigidos a flt3 y uso de los mismosInfo
- Publication number
- CO2022004743A2 CO2022004743A2 CONC2022/0004743A CO2022004743A CO2022004743A2 CO 2022004743 A2 CO2022004743 A2 CO 2022004743A2 CO 2022004743 A CO2022004743 A CO 2022004743A CO 2022004743 A2 CO2022004743 A2 CO 2022004743A2
- Authority
- CO
- Colombia
- Prior art keywords
- flt3
- proteins
- antibodies directed
- pharmaceutical compositions
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962915120P | 2019-10-15 | 2019-10-15 | |
| PCT/US2020/055480 WO2021076554A1 (en) | 2019-10-15 | 2020-10-14 | Antibodies targeting flt3 and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022004743A2 true CO2022004743A2 (es) | 2022-07-08 |
Family
ID=75538063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0004743A CO2022004743A2 (es) | 2019-10-15 | 2022-04-13 | Anticuerpos dirigidos a flt3 y uso de los mismos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240228628A9 (https=) |
| EP (1) | EP4045537A4 (https=) |
| JP (1) | JP2022551757A (https=) |
| KR (1) | KR20220082882A (https=) |
| CN (1) | CN115348972A (https=) |
| AR (1) | AR120222A1 (https=) |
| AU (1) | AU2020366000A1 (https=) |
| BR (1) | BR112022006817A2 (https=) |
| CA (1) | CA3153801A1 (https=) |
| CL (1) | CL2022000927A1 (https=) |
| CO (1) | CO2022004743A2 (https=) |
| IL (1) | IL292259A (https=) |
| MX (1) | MX2022004291A (https=) |
| PE (1) | PE20221256A1 (https=) |
| TW (1) | TWI867066B (https=) |
| WO (1) | WO2021076554A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202091887A1 (ru) | 2018-02-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры |
| DK3749346T3 (da) | 2018-02-08 | 2024-09-09 | Dragonfly Therapeutics Inc | Antistof variable domænekombinationer rettet mod nkg2d-receptoren |
| WO2020033630A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| US12378318B2 (en) | 2018-08-08 | 2025-08-05 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and a tumor-associated antigen |
| EP4291233A4 (en) * | 2021-02-10 | 2025-05-21 | Wugen, Inc. | POLYPEPTIDES AND THEIR USE IN THE TREATMENT OF DISEASES |
| JP2024508894A (ja) | 2021-03-03 | 2024-02-28 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法 |
| US12162940B2 (en) | 2021-05-05 | 2024-12-10 | Immatics Biotechnologies Gmbh | BMA031 antigen binding polypeptides |
| WO2023023491A1 (en) * | 2021-08-16 | 2023-02-23 | Hemogenyx Pharmaceuticals Llc | Anti-flt3 antibodies, cars, car t cells and methods of use |
| WO2023105087A1 (en) * | 2021-12-10 | 2023-06-15 | Tubulis Gmbh | Novel flt3 antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof in combination with tyrosine kinase inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR071891A1 (es) * | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
| NL2014108B1 (en) * | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| ES2884844T3 (es) * | 2015-03-09 | 2021-12-13 | Agensys Inc | Conjugados de anticuerpo fármaco (ADC) que se unen a proteínas FLT3 |
| HK1255234A1 (zh) * | 2015-07-16 | 2019-08-09 | 塞勒兰特治疗公司 | 经半胱氨酸取代的免疫球蛋白 |
| CN118772278A (zh) * | 2017-06-02 | 2024-10-15 | 辉瑞公司 | Flt3的特异性抗体及其用途 |
| JP7317718B2 (ja) * | 2017-06-02 | 2023-07-31 | ファイザー・インク | Ｆｌｔ３を標的にするキメラ抗原受容体 |
| WO2019023097A1 (en) * | 2017-07-26 | 2019-01-31 | Smet Pharmaceutical Inc | ASYMMETRIC BISPECIFIC ANTIBODIES AND THEIR USE |
| TW201930344A (zh) * | 2018-01-12 | 2019-08-01 | 美商安進公司 | 抗ｐｄ-１抗體及治療方法 |
-
2020
- 2020-10-14 EP EP20876423.3A patent/EP4045537A4/en active Pending
- 2020-10-14 KR KR1020227016159A patent/KR20220082882A/ko active Pending
- 2020-10-14 BR BR112022006817A patent/BR112022006817A2/pt not_active Application Discontinuation
- 2020-10-14 WO PCT/US2020/055480 patent/WO2021076554A1/en not_active Ceased
- 2020-10-14 PE PE2022000635A patent/PE20221256A1/es unknown
- 2020-10-14 TW TW109135527A patent/TWI867066B/zh active
- 2020-10-14 JP JP2022522653A patent/JP2022551757A/ja not_active Ceased
- 2020-10-14 MX MX2022004291A patent/MX2022004291A/es unknown
- 2020-10-14 US US17/769,257 patent/US20240228628A9/en active Pending
- 2020-10-14 CA CA3153801A patent/CA3153801A1/en active Pending
- 2020-10-14 CN CN202080072320.1A patent/CN115348972A/zh active Pending
- 2020-10-14 AR ARP200102839A patent/AR120222A1/es unknown
- 2020-10-14 AU AU2020366000A patent/AU2020366000A1/en active Pending
-
2022
- 2022-04-12 CL CL2022000927A patent/CL2022000927A1/es unknown
- 2022-04-13 CO CONC2022/0004743A patent/CO2022004743A2/es unknown
- 2022-04-13 IL IL292259A patent/IL292259A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4045537A1 (en) | 2022-08-24 |
| CN115348972A (zh) | 2022-11-15 |
| WO2021076554A1 (en) | 2021-04-22 |
| TW202124449A (zh) | 2021-07-01 |
| CA3153801A1 (en) | 2021-04-22 |
| BR112022006817A2 (pt) | 2022-07-05 |
| TWI867066B (zh) | 2024-12-21 |
| AU2020366000A1 (en) | 2022-05-12 |
| MX2022004291A (es) | 2022-05-10 |
| PE20221256A1 (es) | 2022-08-16 |
| EP4045537A4 (en) | 2024-07-17 |
| US20240132598A1 (en) | 2024-04-25 |
| AR120222A1 (es) | 2022-02-02 |
| CL2022000927A1 (es) | 2022-10-28 |
| KR20220082882A (ko) | 2022-06-17 |
| IL292259A (en) | 2022-06-01 |
| US20240228628A9 (en) | 2024-07-11 |
| WO2021076554A8 (en) | 2022-04-21 |
| JP2022551757A (ja) | 2022-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022004743A2 (es) | Anticuerpos dirigidos a flt3 y uso de los mismos | |
| CL2023002105A1 (es) | Dominios variables de anticuerpo que se dirigen a cd33 y sus usos | |
| CO2020010345A2 (es) | Dominios variables de anticuerpos que se dirigen al receptor nkg2d | |
| CL2020003071A1 (es) | Proteínas de unión multiespecíficas y mejoras con estas | |
| CO2020016619A2 (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso | |
| EA202091888A1 (ru) | Вариабельные домены антител, нацеленные на рецептор nkg2d | |
| MX2020013169A (es) | Conjugados de camptotecina. | |
| CL2025003689A1 (es) | Anticuerpos de cadena pesada que se unen al psma. | |
| CO2021001410A2 (es) | Proteínas de unión multiespecíficas que se unen a bcma, nkg2d y cd16 y métodos de uso | |
| MX2019011679A (es) | Reemplazo de un pre-acondicionamiento citotoxico antes de una inmunoterapia celular. | |
| MX2024003913A (es) | Anticuerpos dirigidos al receptor del factor activador de celulas b (baff-r) y uso de los mismos. | |
| CO2018011195A2 (es) | Composiciones que comprenden una coformulación de anticuerpos anti-pd-l1 y anti-ctla-4 | |
| AR108468A1 (es) | POLIPÉPTIDOS DE FUSIÓN CD40L-Fc Y MÉTODOS DE USO DE LOS MISMOS | |
| MX2023001556A (es) | Anticuerpos que se dirigen a egfr y uso de los mismos. | |
| CL2018001722A1 (es) | Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506) | |
| MX2022013882A (es) | Anticuerpos dirigidos contra el miembro a de la familia de dominios de lectina tipo c 12 (clec12a) y uso de los mismos. | |
| CO2022007924A2 (es) | Conjugados de anticuerpo y fármaco de eribulina anti-mesotelina y métodos de uso | |
| ECSP20082970A (es) | Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso | |
| ECSP21052193A (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r | |
| AR114102A1 (es) | Anticuerpo biespecífico heterodimérico estructural natural anti-pd-1 / anti-her2 y método para su preparación | |
| MX2022001022A (es) | Anticuerpo biespecifico anti-her2/anti-4-1bb y uso del mismo. | |
| MX2021012967A (es) | Anticuerpos y formulaciones de anti-cd38. | |
| MX2018013484A (es) | Nuevos anticuerpos anti-tnfrsf21 y modos de uso. | |
| MX2022001947A (es) | Anticuerpos que se unen a las proteinas lrp5 y metodos de uso. | |
| AR127897A1 (es) | Anticuerpos dirigidos a 5t4 y usos de estos |